Scotiabank analyst Louise Chen initiated coverage of Regeneron (REGN) with a Sector Perform rating and $650 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron: Strong Buy Rating Backed by Robust Business and Promising Oncology Developments
- Regeneron’s Innovative Anticoagulation Advancements and Market Potential Drive Buy Rating
- Regeneron treatment of pulmonary arterial hypertension granted orphan status
- Sanofi, Regeneron report all primary endpoints met in LIBERTY-AFRS-AIMS study
- Regeneron, Sanofi announces presentation of Phase 3 trial of Dupixent